Pelvic Inflammatory Disease (PID) Treatment Market Report 2026

The pelvic inflammatory disease (pid) treatment market size has grown strongly in recent years. It will grow from $4.74 billion in 2025 to $5 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to high prevalence of sexually transmitted infections, limited awareness of PID, reliance on broad-spectrum antibiotics, delayed diagnosis due to asymptomatic cases, insufficient access to specialized gynecological care.

The pelvic inflammatory disease (pid) treatment market size is expected to see strong growth in the next few years. It will grow to $6.13 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising adoption of combination antibiotic therapy, increasing use of hormonal therapy for prevention, advancements in minimally invasive surgical procedures, expanding telehealth and remote monitoring solutions, growing awareness and education programs for early detection. Major trends in the forecast period include increasing use of ai for early diagnosis and risk stratification, growing adoption of genomics-based personalized treatment approaches, integration of cloud and big data for patient monitoring and management, use of iot-enabled devices for remote symptom tracking, implementation of smart manufacturing in antibiotic production.

The growing prevalence of sexually transmitted infections is expected to drive the growth of the pelvic inflammatory disease (PID) treatment market in the coming years. Sexually transmitted infections (STIs) are infections caused by bacteria, viruses, or parasites that are mainly transmitted through sexual contact, including vaginal, anal, or oral intercourse. The rising incidence of STIs is attributed to factors such as risky sexual behaviors, unprotected sex, limited awareness, delayed testing, and inadequate treatment. Pelvic inflammatory disease (PID) treatment plays an important role in managing STIs by using antibiotics to eliminate infection-causing bacteria, preventing complications such as chronic pelvic pain and infertility, and lowering the risk of recurrent infections. For instance, in October 2024, according to a report published by the UK Health Security Agency (UKHSA), a UK-based government agency, England recorded 6,008 new human immunodeficiency virus (HIV) diagnoses in 2023, representing a 51% increase compared to 3,975 diagnoses in 2022. Therefore, the increasing prevalence of sexually transmitted infections is contributing to the growth of the pelvic inflammatory disease (PID) treatment market.

The increasing adoption of telemedicine is also expected to propel the growth of the pelvic inflammatory disease (PID) treatment market going forward. Telemedicine refers to the remote delivery of healthcare services through digital platforms such as video consultations, mobile health applications, and remote patient monitoring systems. The adoption of telemedicine is rising due to the need for convenient access to healthcare, shortages of healthcare professionals in certain regions, advancements in digital infrastructure, and growing patient preference for virtual consultations. Telehealth solutions support patient care by enabling remote diagnosis and monitoring, improving access to medical services, reducing travel and waiting times, and facilitating timely interventions for both chronic and acute conditions. For instance, in March 2023, according to the Office of the National Coordinator for Health Information Technology (ONC), a US-based government agency, more than 80% of physicians reported using telemedicine for less than 50% of their patients. Therefore, the rising adoption of telemedicine is driving the growth of the pelvic inflammatory disease (PID) treatment market.

Major companies operating in the pelvic inflammatory disease (PID) treatment market are emphasizing the development of innovative formulations, including probiotic supplements, to improve treatment effectiveness, restore vaginal microbiota balance, and reduce infection recurrence among patients. Probiotic supplements contain beneficial live bacteria or yeasts that help maintain or reestablish a healthy balance of gut and vaginal microbiota. For example, in November 2024, Lee Health Domain, an India-based pharmaceutical company, launched V-Ferin, a probiotic supplement formulated to support vaginal health. Developed with Lactobacillus acidophilus, lactoferrin peptide, and cranberry extract, V-Ferin is designed to restore the natural microbiome and help prevent common vaginal infections such as bacterial vaginosis and yeast infections. As approximately 25-30% of women are affected by these conditions, which can progress to pelvic inflammatory disease if left untreated, V-Ferin offers a novel approach to improving women’s health and reducing complications.

Major companies operating in the pelvic inflammatory disease (pid) treatment market are Pfizer Inc., Bayer AG, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Drugs Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Mayne Pharma Group Limited, Saphnix Lifesciences, Aristo Pharmaceuticals Pvt. Ltd., Zydus Cadila Healthcare Ltd., Amagen India Life Sciences.

North America was the largest region in the pelvic inflammatory disease (PID) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pelvic inflammatory disease (pid) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pelvic inflammatory disease (pid) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the pelvic inflammatory disease treatment market by increasing the cost of imported antibiotics, hormonal therapies, and surgical equipment, affecting hospitals and clinics in regions such as North America and Europe. While tariffs have temporarily raised treatment costs, they have also encouraged domestic production, innovation in cost-effective therapies, and optimized supply chains for critical medicines and medical devices.

The pelvic inflammatory disease (pid) treatment market research report is one of a series of new reports that provides pelvic inflammatory disease (pid) treatment market statistics, including pelvic inflammatory disease (pid) treatment industry global market size, regional shares, competitors with a pelvic inflammatory disease (pid) treatment market share, detailed pelvic inflammatory disease (pid) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pelvic inflammatory disease (pid) treatment industry. This pelvic inflammatory disease (pid) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pelvic inflammatory disease (PID) treatment involves the medical management of infections affecting the female reproductive organs, most commonly caused by sexually transmitted bacteria such as *Chlamydia trachomatis and Neisseria gonorrhoeae. The objective of treatment is to eradicate the infection, relieve symptoms, and prevent complications including infertility, chronic pelvic pain, and ectopic pregnancy.

The main types of pelvic inflammatory disease treatment include antibiotic therapy, surgery, pain management, and hormonal therapy. Antibiotic therapy involves the use of antimicrobial agents to treat bacterial infections by eliminating or suppressing bacterial growth. These therapies may be administered orally, intravenously, or intramuscularly, with PID treatments provided across hospitals, clinics, and home care settings.

The pelvic inflammatory disease (PID) treatment market consists of revenues earned by entities by providing services such as medication therapy, pain management, and hospital and clinic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pelvic inflammatory disease (PID) treatment market includes sales of antibiotics, pain relievers, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.